HIV pharmacology workshop report now available online

This article is more than 19 years old.

An extensive report on the Sixth International Workshop on Clinical Pharmacology of HIV Therapy by Mark Mascolini is now available at www.hivpresentation.com. Highlights of the workshop report include:

  • Results of the POPIN study: a randomised study of 122 patients taking either PIs or NNRTIs found no significant virologic or safety benefit to therapeutic drug monitoring plus adherence intervention when compared with standard of care.
  • Once daily protease inhibitor dosing may be more risky than twice daily dosing: missing a single daily PI dose is the equivalent of missing three consecutive twice daily doses.
  • Cases of CD4 decline or blunted CD4 cell recovery have already been reported in people taking tenofovir with ddI. Now a small number of cases have been reported in patients who combined tenofovir with abacavir. Is it a drug interaction?
  • Dose adjustment needed with maraviroc: dose reduction with PIs, dose increase with efavirenz.

Presentations, posters and abstracts from the meeting are also available at the same website.